Pembrolizumab-induced lichenoid dermatitis treated with dupilumab

Bibliographic Details
Main Authors: Jonathan J. Park, PhD, Eunsuh Park, William E. Damsky, MD, PhD, Matthew D. Vesely, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-07-01
Series:JAAD Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352512623001534
_version_ 1827903536361373696
author Jonathan J. Park, PhD
Eunsuh Park
William E. Damsky, MD, PhD
Matthew D. Vesely, MD, PhD
author_facet Jonathan J. Park, PhD
Eunsuh Park
William E. Damsky, MD, PhD
Matthew D. Vesely, MD, PhD
author_sort Jonathan J. Park, PhD
collection DOAJ
first_indexed 2024-03-13T00:14:22Z
format Article
id doaj.art-4bfe430ae6354af59581442d2dcc3c46
institution Directory Open Access Journal
issn 2352-5126
language English
last_indexed 2024-03-13T00:14:22Z
publishDate 2023-07-01
publisher Elsevier
record_format Article
series JAAD Case Reports
spelling doaj.art-4bfe430ae6354af59581442d2dcc3c462023-07-12T04:19:50ZengElsevierJAAD Case Reports2352-51262023-07-01371315Pembrolizumab-induced lichenoid dermatitis treated with dupilumabJonathan J. Park, PhD0Eunsuh Park1William E. Damsky, MD, PhD2Matthew D. Vesely, MD, PhD3Department of Genetics, Yale School of Medicine, New Haven, Connecticut; Department of Dermatology, Yale School of Medicine, New Haven, ConnecticutDepartment of Dermatology, Yale School of Medicine, New Haven, ConnecticutDepartment of Dermatology, Yale School of Medicine, New Haven, Connecticut; Department of Pathology, Yale School of Medicine, New Haven, ConnecticutDepartment of Dermatology, Yale School of Medicine, New Haven, Connecticut; Correspondence to: Matthew D. Vesely, MD, PhD, Department of Dermatology, Yale School of Medicine, 333 Cedar St, PO Box 208059, New Haven, CT 06510.http://www.sciencedirect.com/science/article/pii/S2352512623001534cancer immunotherapycutaneous immune related adverse eventsdupilumabimmune checkpointlichen planuslichenoid dermatitis
spellingShingle Jonathan J. Park, PhD
Eunsuh Park
William E. Damsky, MD, PhD
Matthew D. Vesely, MD, PhD
Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
JAAD Case Reports
cancer immunotherapy
cutaneous immune related adverse events
dupilumab
immune checkpoint
lichen planus
lichenoid dermatitis
title Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
title_full Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
title_fullStr Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
title_full_unstemmed Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
title_short Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
title_sort pembrolizumab induced lichenoid dermatitis treated with dupilumab
topic cancer immunotherapy
cutaneous immune related adverse events
dupilumab
immune checkpoint
lichen planus
lichenoid dermatitis
url http://www.sciencedirect.com/science/article/pii/S2352512623001534
work_keys_str_mv AT jonathanjparkphd pembrolizumabinducedlichenoiddermatitistreatedwithdupilumab
AT eunsuhpark pembrolizumabinducedlichenoiddermatitistreatedwithdupilumab
AT williamedamskymdphd pembrolizumabinducedlichenoiddermatitistreatedwithdupilumab
AT matthewdveselymdphd pembrolizumabinducedlichenoiddermatitistreatedwithdupilumab